Uniphar

Uniphar Debt

The Debt of Uniphar (UPR.IR) as of Nov 12, 2026 is 355.07 M EUR. In the previous year, Debt was 241.65 M EUR — a change of 46.94% (higher).

Debt

355.07 MEUR

YoY

46.94%

Last updated:

In 2025, Uniphar's total debt was 355.07 M EUR, a 46.94% change from the 241.65 M EUR total debt recorded in the previous year.

The Uniphar Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
165.80 M EUR
Jan 1, 2019
182.54 M EUR
Jan 1, 2020
218.46 M EUR
Jan 1, 2021
245.40 M EUR
Jan 1, 2022
187.43 M EUR
Jan 1, 2023
222.60 M EUR
Jan 1, 2024
241.65 M EUR
Jan 1, 2025
355.07 M EUR
The Uniphar Debt history
YEARDebtYoY
355.07 MEUR+46.94%
241.65 MEUR+8.55%
222.60 MEUR+18.77%
187.43 MEUR-23.62%
245.40 MEUR+12.33%
218.46 MEUR+19.68%
182.54 MEUR+10.10%
165.80 MEUR+203.91%
54.56 MEUR-15.25%
64.37 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Uniphar Stock analysis

What does Uniphar do? Uniphar PLC is an Irish company that was founded in 1994 and operates in the healthcare industry. The company is headquartered in Dublin and employs over 2,500 people worldwide. The history of Uniphar began as a pharmacy distribution company that supplied medications to retailers and healthcare facilities. Over the years, however, the company has expanded its business model and now offers a wide range of healthcare products and services. Uniphar's business model encompasses three main areas: Healthcare Services, Commercial & Clinical Supply Chain, and Product Access & Specialty Medicines. In the Healthcare Services area, Uniphar provides consulting services, training, and leadership coaching for healthcare facilities. The Commercial & Clinical Supply Chain division includes the storage, logistics, and distribution of medications, as well as the clinical care of patients. The Product Access & Specialty Medicines division focuses on access to medications with high medical demand and rare diseases. Uniphar also offers a wide range of healthcare products, including generics, branded medications, and medical devices. The company has partnerships with leading pharmaceutical companies such as Pfizer, Eli Lilly, and Merck. In recent years, Uniphar has also made several significant acquisitions to expand and diversify its business. In 2018, the company acquired UK-based pharmaceutical distributor Cahill May Roberts, and in 2019, the acquisition of Durbin, an international supplier of clinical supply products, was completed. Uniphar is committed to improving healthcare in Ireland and worldwide and offers a wide range of products and services to achieve this goal. The company has earned a reputation as a reliable partner for healthcare facilities and pharmaceutical companies and is on a steady growth trajectory. Uniphar is one of the most popular companies on Eulerpool.

Debt Details

Understanding Uniphar's Debt Structure

Uniphar's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Uniphar's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Uniphar’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Uniphar’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Uniphar stock

Debt of Uniphar is 355.07 M EUR in 2025.

Debt of Uniphar changed from 241.65 M EUR to 355.07 M EUR, representing a 46.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Uniphar since 2006 – with annual values, charts, and detailed analysis.

Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Uniphar historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Uniphar

All Key Metrics — Uniphar